BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX)
CUSIP: 09058V103
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 210,587,372
- Total 13F shares
- 197,129,798
- Share change
- +21,825,587
- Total reported value
- $1,766,723,682
- Put/Call ratio
- 59%
- Price per share
- $8.96
- Number of holders
- 292
- Value change
- +$203,493,373
- Number of buys
- 163
- Number of sells
- 113
Quarterly Holders Quick Answers
What is CUSIP 09058V103?
CUSIP 09058V103 identifies BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 09058V103:
Top shareholders of BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
8.4%
from 13D/G
|
22,769,246
|
$170,769,349 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
10%
|
21,659,765
|
$162,448,239 | — | 31 Mar 2025 | |
| Avoro Capital Advisors LLC |
13D/G
13F
|
Company |
4.2%
|
8,700,000
|
$71,514,000 | $0 | 31 Mar 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
4.2%
|
8,928,523
|
$66,963,923 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.7%
|
7,813,404
|
$58,600,530 | — | 31 Mar 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.4%
|
7,214,021
|
$54,105,158 | — | 31 Mar 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
2.5%
|
5,189,665
|
$38,922,488 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.4%
|
4,960,637
|
$37,213,423 | — | 31 Mar 2025 | |
| RP Management, LLC |
13F
|
Company |
1.8%
|
3,846,154
|
$28,846,155 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.8%
|
3,812,874
|
$28,596,555 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.5%
|
3,220,712
|
$24,155,340 | — | 31 Mar 2025 | |
| Caligan Partners LP |
13F
|
Company |
1.5%
|
3,107,669
|
$23,307,518 | — | 31 Mar 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
1.4%
|
3,052,137
|
$22,891,027 | — | 31 Mar 2025 | |
| GW&K Investment Management, LLC |
13F
|
Company |
1.4%
|
2,884,680
|
$21,635,000 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
1.1%
|
2,403,186
|
$18,023,896 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.68%
|
1,423,646
|
$17,233,912 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.1%
|
2,297,674
|
$17,232,567 | — | 31 Mar 2025 | |
| Eversept Partners, LP |
13F
|
Company |
1%
|
2,172,436
|
$16,293,270 | — | 31 Mar 2025 | |
| JUPITER ASSET MANAGEMENT LTD |
13F
|
Company |
1%
|
2,148,969
|
$16,117,268 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.97%
|
2,045,535
|
$15,341,513 | — | 31 Mar 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.97%
|
2,033,783
|
$15,253,372 | — | 31 Mar 2025 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.96%
|
2,027,568
|
$15,206,760 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.93%
|
1,955,258
|
$14,664,437 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.92%
|
1,931,934
|
$14,489,506 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.91%
|
1,922,038
|
$14,415,285 | — | 31 Mar 2025 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.87%
|
1,836,979
|
$13,777,343 | — | 31 Mar 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.83%
|
1,747,306
|
$13,104,795 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.75%
|
1,589,112
|
$11,918,340 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.68%
|
1,435,657
|
$10,767,430 | — | 31 Mar 2025 | |
| SEGALL BRYANT & HAMILL, LLC |
13F
|
Company |
0.63%
|
1,330,314
|
$9,977,355 | — | 31 Mar 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.63%
|
1,324,221
|
$9,931,658 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.57%
|
1,201,449
|
$9,010,871 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.51%
|
1,065,583
|
$7,991,874 | — | 31 Mar 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.5%
|
1,042,424
|
$7,818,180 | — | 31 Mar 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.48%
|
1,000,562
|
$7,504,215 | — | 31 Mar 2025 | |
| Legal & General Group Plc |
13F
|
Company |
0.47%
|
981,218
|
$7,359,135 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.46%
|
968,155
|
$7,261,164 | — | 31 Mar 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.46%
|
960,057
|
$7,200,000 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.45%
|
940,665
|
$7,054,988 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.38%
|
800,000
|
$6,000,000 | — | 31 Mar 2025 | |
| PDT Partners, LLC |
13F
|
Company |
0.37%
|
778,729
|
$5,840,468 | — | 31 Mar 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.36%
|
764,898
|
$5,736,735 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.32%
|
670,361
|
$5,023,000 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.29%
|
612,324
|
$4,803,112 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.29%
|
612,219
|
$4,591,641 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.29%
|
605,218
|
$4,539,135 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.28%
|
589,877
|
$4,424,080 | — | 31 Mar 2025 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
0.28%
|
589,310
|
$4,419,825 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.28%
|
586,206
|
$4,396,545 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.28%
|
583,614
|
$4,377,109 | — | 31 Mar 2025 |
Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX) as of Q2 2025
As of 30 Jun 2025,
BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX) was held by
292 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
197,129,798 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, STATE STREET CORP, Kynam Capital Management, LP, ALKEON CAPITAL MANAGEMENT LLC, UBS Group AG, MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., and Avoro Capital Advisors LLC.
This page lists
292
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
273
Q2 2025 holders
292
Holder diff
19
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.